Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents

Rassi, 2010, Chagas disease, Lancet, 375, 1388, 10.1016/S0140-6736(10)60061-X Lescure, 2010, Chagas disease: changes in knowledge and management, The Lancet Infectious Diseases, 10, 556, 10.1016/S1473-3099(10)70098-0 Coura, 2010, Chagas disease: 100 years after its discovery. A systemic review, Acta Tropica, 115, 5, 10.1016/j.actatropica.2010.03.008 2010 www.paho.org/chagas. Schmunis, 2007, Epidemiology of Chagas disease in non-endemic countries: the role of international migration, Memorias do Instituto Oswaldo Cruz, 102, 75, 10.1590/S0074-02762007005000093 Schmunis, 2010, Chagas disease: a Latin American health problem becoming a world health problem, Acta Tropica, 115, 14, 10.1016/j.actatropica.2009.11.003 Kirchhoff, 2011, Epidemiology of American trypanosomiasis (Chagas disease), Advances in Parasitology, 75, 1, 10.1016/B978-0-12-385863-4.00001-0 Dias, 2002, The impact of Chagas disease control in Latin America: a review, Memorias do Instituto Oswaldo Cruz, 97, 603, 10.1590/S0074-02762002000500002 Urbina, 2003, Specific chemotherapy of Chagas disease: controversies and advances, Trends in Parasitology, 19, 495, 10.1016/j.pt.2003.09.001 Urbina, 2010, Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches, Acta Tropica, 115, 55, 10.1016/j.actatropica.2009.10.023 Coura, 2002, A critical review on Chagas disease chemotherapy, Memorias do Instituto Oswaldo Cruz, 97, 3, 10.1590/S0074-02762002000100001 Coura, 2010, Chagas disease: a new worldwide challenge, Nature, 465, S6, 10.1038/nature09221 Carta, 2005, Quinoxaline 1,4-dioxide: a versatile scaffold endowed with manifold activities, Current Medicinal Chemistry, 12, 2259, 10.2174/0929867054864831 González, 2007, Quinoxaline 1,4-dioxide and phenazine 5,10-dioxide. Chemistry and biology, Topics in Heterocyclic Chemistry, 11, 179, 10.1007/7081_2007_066 Zarranz, 2004, Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives, Bioorganic & Medicinal Chemistry, 12, 3711, 10.1016/j.bmc.2004.04.013 Solano, 2007, Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues, Journal of Medicinal Chemistry, 50, 5485, 10.1021/jm0703993 Moreno, 2010, Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives, European Journal of Medicinal Chemistry, 45, 4418, 10.1016/j.ejmech.2010.06.036 Ancizu, 2009, Heterocyclic-2-carboxylic acid (3-cyano-1,4-di-N-oxidequinoxalin-2-yl)amide derivatives as hits for the development of neglected disease drugs, Molecules, 14, 2256, 10.3390/molecules14062256 Aguirre, 2004, Quinoxaline N,N′-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure–activity relationships, Bioorganic & Medicinal Chemistry Letters, 14, 3835, 10.1016/j.bmcl.2004.04.088 Vicente, 2010, Anti-T. cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides, Bioorganic & Medicinal Chemistry Letters, 20, 4831, 10.1016/j.bmcl.2010.06.101 Torres, 2011, New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-mycobacterium tuberculosis agents, Bioorganic & Medicinal Chemistry Letters, 21, 3699, 10.1016/j.bmcl.2011.04.072 Burguete, 2011, Synthesis and biological evaluation of new quinoxaline derivatives as antioxidant and anti-inflammatory agents, Chemical Biology & Drug Design, 77, 255, 10.1111/j.1747-0285.2011.01076.x Barea, 2011, New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities, Bioorganic & Medicinal Chemistry Letters, 21, 4498, 10.1016/j.bmcl.2011.05.125 Barea, 2012, Antiplasmodial and leishmanicidal activities of 2-cyano-3-(4-phenylpiperazine-1-carboxamido) quinoxaline 1,4-dioxide derivatives, Molecules, 17, 9451, 10.3390/molecules17089451 Vicente, 2008, Synthesis and antiplasmodial activity of 3-furyl and 3-thienylquinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives, Molecules, 13, 69, 10.3390/molecules13010069 Benitez, 2011, 3-Trifluoromethylquinoxaline N,N′-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies, Journal of Medicinal Chemistry, 54, 3624, 10.1021/jm2002469 Mavandadi, 2006, The impact of microwave-assisted organic synthesis in drug discovery, Drug Discovery Today, 11, 165, 10.1016/S1359-6446(05)03695-0 Larhed, 2001, Microwave-assisted high-speed chemistry: a new technique in drug discovery, Drug Discovery Today, 6, 406, 10.1016/S1359-6446(01)01735-4 Kappe, 2006, The impact of microwave synthesis on drug discovery, Nature Reviews Drug Discovery, 5, 51, 10.1038/nrd1926 Wathey, 2002, The impact of microwave-assisted organic chemistry on drug discovery, Drug Discovery Today, 7, 373, 10.1016/S1359-6446(02)02178-5 Ancizu, 2010, New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-mycobacterium tuberculosis agents, Bioorganic & Medicinal Chemistry, 18, 2713, 10.1016/j.bmc.2010.02.024 Boiani, 2008, Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies, Bioorganic & Medicinal Chemistry, 16, 7900, 10.1016/j.bmc.2008.07.077 Boiani, 2010, Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved?, Biochemical Pharmacology, 79, 1736, 10.1016/j.bcp.2010.02.009 Ames, 1975, Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test, Mutation Research, 31, 347, 10.1016/0165-1161(75)90046-1 Ortega, 2002, Anti-Mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide, Arzneimittel-Forschung, 52, 113 Faucher, 1995, Detection of an “epimastigote-like” intracellular stage of Tripanosma cruzi, Parasitology Research, 81, 441, 10.1007/BF00931508 Almeida-de Faría, 1999, Trypanosoma cruzi: characterization of an intracellular epimastigote-like form, Experimental Parasitology, 92, 263, 10.1006/expr.1999.4423 Tyler, 2001, The life cycle of Trypanosoma cruzi revisited, International Journal of Parasitology, 31, 472, 10.1016/S0020-7519(01)00153-9 Bonnet-Delpon, 2008, Fluorine, an essential element for medicinal chemistry, Annales Pharmaceutiques Francaises, 66, 56, 10.1016/j.pharma.2007.12.001 Purser, 2008, Fluorine in medicinal chemistry, Chemical Society Reviews, 37, 320, 10.1039/B610213C Shah, 2007, The role of fluorine in medicinal chemistry, Journal of Enzyme Inhibition and Medicinal Chemistry, 22, 527, 10.1080/14756360701425014 Porcal, 2007, Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure–activity relationships, Bioorganic & Medicinal Chemistry, 15, 2768, 10.1016/j.bmc.2007.01.009 Rieger, 1994 Bard, 2001 Ryan, 1985, Charge transfer in the mechanism of drug action involving quinoxaline di-N-oxides, Journal of Pharmaceutical Sciences, 74, 492, 10.1002/jps.2600740427 Crawford, 1986, Cyclic voltammetry of phenazines and quinoxalines including mono- and di-N-oxides. Relation to structure and antimicrobial activity, Chemico-Biological Interactions, 60, 67, 10.1016/0009-2797(86)90018-9 Ames, 1992, Cyclic voltammetry of some quinoxaline di-N-oxides and quinoxalines in dimethylformamide, Electrochimica Acta, 37, 1433, 10.1016/0013-4686(92)87018-U Miyazaki, 1981, Cyclic voltammetry of aromatic amine N-oxides in nonaqueous solvents and the stability of the free radicals produced, Bulletin of the Chemical Society of Japan, 54, 3850, 10.1246/bcsj.54.3850 Moreno, 2011, 1,4-Di-N-oxide quinoxaline-2-carboxamide: cyclic voltammetry and relationship between electrochemical behavior, structure and anti-tuberculosis activity, Electrochimica Acta, 56, 3270, 10.1016/j.electacta.2011.01.030 Pérez-Silanes, 2013, Cyclic voltammetric study of some anti-Chagas active quinoxaline 1,4-di-N-oxide-2-ketone derivatives, Helvetica Chimica Acta, 96, 217, 10.1002/hlca.201200085 Barqawi, 1987, A cyclic voltammetric study of some quinoxaline di-N-oxides and quinoxalines in acetonitrile: substituent effect on the cathodic reduction, Electrochimica Acta, 32, 597, 10.1016/0013-4686(87)87047-0 Zuman, 1967 Aguirre, 2002, Benzo[1,2-c]1,2,5-oxadiazole N-oxide derivatives as potential antitrypanosomal drugs. Structure–activity relationships. Part II, Archiv der Pharmazie, 335, 15, 10.1002/1521-4184(200201)335:1<15::AID-ARDP15>3.0.CO;2-8 Aguirre, 2004, Novel antiprotozoal products: imidazole and benzimidazole N-oxide derivatives and related compounds, Archiv der Pharmazie, 337, 259, 10.1002/ardp.200300840 Aguirre, 2005, New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: quantitative structure–activity relationship studies, Bioorganic & Medicinal Chemistry, 13, 6336, 10.1016/j.bmc.2005.07.072 Caterina, 2008, Imidazolidines as new anti-Trypanosoma cruzi agents: biological evaluation and structure–activity relationships, Bioorganic & Medicinal Chemistry, 16, 2226, 10.1016/j.bmc.2007.11.077 Aran, 2005, Synthesis and biological properties of new 5-nitroindazole derivatives, Bioorganic & Medicinal Chemistry, 13, 3197, 10.1016/j.bmc.2005.02.043 Gerpe, 2009, 5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene, Bioorganic & Medicinal Chemistry, 17, 7500, 10.1016/j.bmc.2009.09.013 Maron, 1983, Revised methods for the Salmonella mutagenicity test, Mutation Research, 113, 173, 10.1016/0165-1161(83)90010-9 Mortelmans, 2000, The Ames Salmonella/microsome mutagenicity assay, Mutation Research, 455, 29, 10.1016/S0027-5107(00)00064-6 Cabrera, 2009, Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction, Toxicology Letters, 190, 140, 10.1016/j.toxlet.2009.07.006 Guengerich, 2006, Cytochrome P450s and other enzymes in drug metabolism and toxicity, The AAPS Journal, 8, E101, 10.1208/aapsj080112 Chu, 1981, Evaluating statistical analyses and reproducibility of microbial mutagenicity assays, Mutation Research, 85, 119, 10.1016/0165-1161(81)90027-3 Gritzner, 1984, Recommendations on reporting electrode potentials in nonaqueous solvents, Pure Applied Chemistry, 56, 461, 10.1351/pac198456040461 Strier, 1958, The polarography of quinoxaline II. 6-Substituted derivatives, Journal of American Chemical Society, 80, 1565, 10.1021/ja01540a014